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Background: For nearly two decades now, various studies have reported detecting the Epstein-Barr virus (EBV) in
breast cancer (BC) cases. Yet the results are unconvincing, and their interpretation has remained a matter of debate.
We have now presented prospective data on the effect of EBV infection combined with survival in patients enrolled
in a prospective study.
Methods: We assessed 85 BC patients over an 87-month follow-up period to determine whether EBV infection,
evaluated by qPCR in both peripheral blood mononuclear cells (PBMCs) and tumor biopsies, interacted with host
cell components that modulate the evolution parameters of BC. We also examined the EBV replicating form by the
titration of serum anti-ZEBRA antibodies. Immunological studies were performed on a series of 35 patients randomly
selected from the second half of the survey, involving IFN-γ and TNF-α intracellular immunostaining tests performed
via flow cytometry analysis in peripheral NK and T cells, in parallel with EBV signature. The effect of the EBV load in
the blood or tumor tissue on patient survival was analyzed using univariate and multivariate analyses, combined
with an analysis of covariance.
Results: Our study represents the first ever report of the impact of EBV on the clinical outcome of BC patients,
regardless of tumor histology or treatment regimen. No correlation was found between: (i) EBV detection in tumor
or PBMCs and tumor characteristics; (ii) EBV and other prognostic factors. Notably, patients exhibiting anti-ZEBRA
antibodies at high titers experienced poorer overall survival (p = 0.002). Those who recovered from their disease
were found to have a measurable EBV DNA load, together with a high frequency of IFN-γ and TNF-α producing
PBMCs (p = 0.04), which indicates the existence of a Th1-type polarized immune response in both the tumor and its
surrounding tissue.
Conclusions: The replicative form of EBV, as investigated using anti-ZEBRA titers, correlated with poorer outcomes,
whereas the latent form of the virus that was measured and quantified using the EBV tumor DNA conferred a
survival advantage to BC patients, which could occur through the activation of non-specific anti-tumoral immune
responses.
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Breast cancer (BC), the most common cancer in women,
is considered a heterogeneous disease with pathological
characteristics such as morphology, grade, and hormone-
receptor profile used in order to stratify tumors into
biologically- and clinically-distinct groups [1]. For
nearly two decades now, reports have suggested that the
Epstein–Barr virus (EBV) [2] may constitute a putative
factor in BC natural history [3]. Since 1995, various studies
have reported detecting the EBV in BC cases [4-14]. Yet
the results remain unconvincing, and their interpretation
has been a matter of debate for several years [15-22]. A
link between the EBV and BC was first proposed when
two studies detected EBV DNA in whole tumor material
in 50% of their studied cases [7]. Following this report,
other authors detected EBER-2 and LMP-2 DNA by poly-
merase chain reaction (PCR) in 51% of breast cancers,
compared to only 10% in normal tissue from the same pa-
tients, thus demonstrating that the EBV could be re-
stricted to tumor epithelial cells [8,23]. In their study
combining laser capture microdissection techniques with
real-time quantitative PCR, Arbach et al. detected EBV ge-
nomes in approximately 50% of BC specimens [4], reveal-
ing viral loads which greatly varied from tumor to tumor.
Another issue has also been addressed in a previous publi-
cation comparing EBV DNA levels in peripheral blood
with the viral load in the tumor specimens [14]. Interest-
ingly, the authors of both studies reported finding EBV in
the tumor specimens, yet no EBV genomic DNA in per-
ipheral blood, which is consistent with the epithelial
localization of the virus. This controversy was later re-
solved by others, with publications reporting a strict
correlation between EBNA-1 expression and EBV DNA
detection by PCR [11], although the detection of EBV
(protein expression and DNA detection), in terms of it
being restricted to tumor epithelial cells, is still a de-
bated issue.
As concerns the impact of the EBV on disease progno-
sis and evolution, only few studies have clearly addressed
the relevant conclusions resulting from various trials
[8,18,24]. These included, for the most part, contradict-
ory conclusions: (i) some authors demonstrated that the
EBV might be associated with aggressive BC forms
[4,6,8], or may enhance tumorigenic activity [25]; (ii) on
the other hand, other studies mentioned the absence of
EBV detection in tumor tissue [16,17,18]; (iii) others
demonstrated that the EBV played no relevant role in
BC pathogenesis [10].
Here, we have presented prospective data on the effect
of EBV infection combined with survival in 85 patients en-
rolled in a prospective study. Our study aims were concen-
trated into three axes: i) EBV DNA detection in both BC
tissue and peripheral blood mononuclear cells (PBMCs);
ii) the IFN-γ and TNF-α intracellular immunostaining testcombined with flow cytometry analysis, chosen owing to
the fact that cytokines, primarily secreted by activated T
cells and natural liller cells, play a crucial role in the re-
sponse to persistent viral infections [26]; iii) patient clinical
outcome and pathological characteristics. Our results
demonstrate that the detection of EBV infection, together
with immunological studies, could help predict disease
outcome in terms of patient survival.
Methods
Patients
A total of 85 BC patients were enrolled in the study
(Portuguese female patients, primarily at the postmeno-
pausal stage). Their age at diagnosis ranged from 34 to
83 years. The study included only patients diagnosed and
treated at the Gynecology Unit of the Coimbra University
Hospital, which is the principal general hospital in this
area of Portugal, covering a both rural and urban popula-
tion of approximately 2.3 million people. The size of this
population has already been well described in a previous
study [27]. BC diagnosis and the histopronostic Scarff-
Bloom-Richardson classification (SBR) were conducted
using the relevant criteria, as previously described [28].
The treatment protocol for invasive BC was designed in
accordance with the 5th National Consensus for Breast
Cancer (see Additional file 1). Each patient was classified
according to the TNM (tumor-nodes-metastasis) system.
The protocol was approved by the medical Ethics Com-
mittee of the Coimbra University Hospital (Portugal). The
informed consent was obtained from every patient and
from every healthy control donor.
Tumor samples
These were collected prior to chemotherapy or radio-
therapy in accordance with the protocols defined in the
National Statement on Human Research Involving
Humans. On collection, the formalin-fixed and paraffin-
embedded tissues were divided into three parts: the first
to be submitted for conventional histological study; the
second assayed for estrogen and progesterone receptors;
the third used in molecular biology assays. Total tumor
DNA was extracted from a 10 μm section from each bi-
opsy, as previously described [19].
Blood samples
Prior to any treatment, 50 ml of whole blood were collected
into heparinized tubes from both BC patients and controls
(totaling 16 healthy blood donors). Firstly, total peripheral
blood mononuclear cells (PBMCs) were isolated by Ficoll
density gradient centrifugation (Lymphoprep©, Eurobio
France). Enriched PBMCs (1.5 107 cells/0.5 mL) were im-
mediately stored in cryotubes, with 20% DMSO, at −80°C
for 48 hours, then frozen in liquid nitrogen until brought
out for use. DNA was isolated from the PBMCs by means
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Germany) and then quantified. The second step consisted
of serum sample collection, with the DNA from 200 μL of
serum samples extracted using the same protocol.
EBV detection by real-time quantitative Light Cycler (LC)-
PCR
The amplification and quantification of the EBV DNA
were both assessed by real-time PCR on an LC appar-
atus (Roche Diagnostics), as previously described [29].
An equivalent of 0.5 μg of extracted DNA was used in
the PCR. Standard curves for the quantification of EBV
DNA were generated using 10-fold serial dilutions of
Namalwa cell DNA. In parallel with this, genomic DNA
was also quantified for amplification by means of a ribo-
somal DNA probe/primer set (Eukaryotic 18S rRNA En-
dogenous Control, Applied Biosystems) as an internal
efficiency control. The samples were measured in dupli-
cate. For all samples taken from the 85 patients, the re-
sults were given as EBV copy number per μg of total
extracted DNA, with a lower detection limit of 5 and 10
copies EBV DNA/μg for PBMCs and tumor biopsies,
respectively.
EBV-related serology
In all patients, EBV serology was determined using two
different methods: (i) conventional indirect immuno-
fluorescence assays (IFA) were performed to measure
anti-VCA IgGs and anti-early antigens (EA); (ii) we also
investigated the reactivation of the lytic cycle through an
ELISA titration of the anti-ZEBRA IgGs, as previously
described [30,31]. The results were expressed as optical
density (OD) and translated by Pearson’s correlation
analysis in order to determine the corresponding anti-
ZEBRA antibody titers (1OD ≈ 5000).
Immunological studies
Immunological studies were performed on the series of 35
patients randomly selected from the second half of the
survey. These patients did not differ from the other 50 in
terms of diagnostic age, menopausal status, tumor sub-
type, and EBV DNA load in tumor tissue (p = 0.58) (see
Additional file 2: Figure S3). The studies consisted firstly
(i) of T and NK cell stimulation, conducted to assess T-
and NK-cell ability to produce IFN-γ and TNF-α in re-
sponse to PMA/ionomycin in vitro stimulation. For this,
0.5 mL heparinized blood samples taken from BC patients
and female controls were diluted into an equal volume
of RPMI 1640 medium. The cells were then stimulated
with 50 ng/ml phorbol 12-myristate 13-acetate (PMA;
Sigma), and 1 mg/mL ionomycin (Boehringer Mannheim,
Germany) in RPMI-1640 medium, containing 10% heat-
inactivated fetal calf serum (FCS), 2 mM glutamine, 1%
penicillin-streptomycin (Gibco), and 10 μg/mL BrefeldinA (Golgi plug, Sigma, Saint Louis, MO, USA). Unstimu-
lated samples were set up in parallel, but without PMA
and ionomycin. Finally, the tubes were incubated for 4 h
at 37°C in a humid atmosphere with 5% CO2 concentra-
tion. The second study (ii) consisted of cellular staining
and flow cytometry, including the indirect staining of
intracellular cytokines and cell surface molecules, per-
formed throughout according to the manufacturer’s in-
structions. For a brief description, cells were stained by
means of conjugated mAbs PerCP-CD3 and APC-CD56
or APC-CD57 (Pharmingen BDB), directed against T lym-
phocytes and NK subsets, respectively. The cells were then
washed with PBS, fixed, and permeabilized with a Fix &
Perm kit. Cells were incubated with anti-IFN-γ-FITC
(clone 4S.B3, Pharmingen BDB) and anti-PE-TNF-α (clone
Mab11, Pharmingen BDB) antibodies, then washed with
PBS, and fixed with 0.5% paraformaldehyde in PBS. The
cells (1×104) were analyzed on FACSCalibur flow cyt-
ometer using Cell-Quest (BD Biosciences) and Paint-A-
Gate 3.0.2 PPC© software (BDB, Coimbra).
Survival analysis
Our data consisted of overall patient survival (S), defined
as the probability that the patient is still alive (S = 1) at a
specific time (“t”) during the study period, covering the
time of BC clinical diagnosis to the cut-off date of De-
cember 2010. During that period, all patients were ini-
tially alive (i.e., with S = 1) and may either have gone on
to die (therefore S = 0) or stay alive, and may or may not
have experienced relapse events, where patients having
had surgery suffered from tumor relapse after a disease-
free period. The survival analysis was established in
order to investigate the effect of EBV infection and other
clinicopathological factors on BC patient survival (S). To
this end, Cox proportional hazards analyses for S were
conducted, applying eight clinicopathological explicative
variables or covariates, including: EBV detected in PBMCs
(EBV-P) or tumors (EBV-T), relapse, tumor size, lymph
node invasion, histological grade (Grade), estrogen/pro-
gesterone receptor (ER/PR) status, HER-2 status (HER2),
and anti-ZEBRA antibody titration. These were the only
eight variables available in the database. The treatment
variable was not included in the analyses due to the het-
erogeneous distribution of treatments with only a very
small number of patients in several treatment classes (see
Additional file 1).
We proceeded with the following two steps. Step 1: for
verification purposes, univariate Cox proportional haz-
ards analyses were performed to calculate patient sur-
vival S with each clinicopathological explicative variable
X consisting of S(t) = exp{−h(t)}, with the hazard func-
tion h(t) given by h(t) = h0(t) × exp{βX}, where h0(t) is
the baseline and β the regression coefficient associated
with the variable X. Pearson correlations between all
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lated variables. Step 2: two multivariate Cox models
were developed for S with non-correlated clinicopatho-
logical variables, excluding and including EBV variables,
respectively. For each Cox model, we used the hazard









where h0(t) and β represent the same value, as with the
univariate analysis, and the coefficient γ accounts for in-
teractions between variables. All combinations in this
hazard function were tested leading to several models,
and the model with the lowest AIC (Akaike information
criterion) was retained as the best. Following this, the
two best models, both excluding and including EBV,
were compared for the purposes of assessing the effect
of EBV status on patient survival. All statistical analyses
were carried out using the free software R Version 2.12.2
(2011-02-25), (Copyright 2011 The R Foundation for
Statistical Computing). In R, we applied the functions
“coxph” for Cox analyses and “stepAIC” for selecting the
best model, according to AIC. Survivor functions were
estimated using the Kaplan–Meier method, while hazard
ratios or relative risks, given as RRi = exp(βi) or RRi,j =
exp(γi,j), associated with explicative variables were pre-
sented with their corresponding 95% confidence inter-
vals (95% CI), and statistical tests were performed at the
5% significance level (p <0.05). In this context, RR >1
corresponds to a negative effect, i.e. a decrease in patient
survival, while a RR <1 corresponds to a positive effect,
i.e. an increase in patient survival (“95% CI” stands for
the confidence interval at 95%).
Results
Global results and EBV status
All the patients enrolled in this study were EBV-
seropositive (detectable anti-VCA and anti-EBNA IgGs).
The histopathologic types of the breast tumors analyzed,
as well as patient characteristics, have been summarized in
(see Additional file 3: Table S1). In the total 85 whole-
blood samples obtained from female BC patients, 40
(47%) were revealed as positive (EBV-P+ patients) by PCR,
with EBV DNA copies ranging from 10 to 2360 copies/μg
blood (median: 100 EBV DNA copies/μg). EBV DNA de-
tection was then measured on 85 paraffin-embedded tis-
sues, with 22 out of 85 (25.8%) revealed as positive for
EBV (EBV-T+ patients) and EBV DNA copies ranging
from 10 to 2950 copies/μg (median: 84 EBV DNA copies/
μg). In comparison, three PBMC samples from 16 healthy
control individuals contained EBV DNA (median: 0
copies/μg DNA). None of the 85 tumors in this study had
to be excluded due to inadequate control amplification.
Given that we examined EBV DNA load in both neo-
plastic breast tissue and matched peripheral blood, nocorrelation was found between EBV loads in blood and tu-
mors. It is interesting to note that the viral load was highly
variable from tumor to tumor (Figure 1A). The proportion
of BC patients negative for EBV DNA in both PBMCs and
paraffin embedded tissues (EBV-P−/EBV-T−) reached 27%.
For a brief overview, no association could be established
between EBV load (PBMCs and tumor) and other prog-
nostic factors, including age at diagnosis, tumor size, and
lymph node invasion (see Additional file 4: Figures S2A,
S2B, S2C, and S2D). Patients without relapse were more
likely to exhibit detectable EBV DNA in their blood, as
well as EBV to some extent in their tumor. By using the
Mann–Whitney test, we revealed that the virus did not
seem to have any significant effect on overall survival (p >
0.05), though this result was further tested by means of
univariate and multivariate analyses. In another series of
experiments exploring reactivating EBV, we investigated
the presence of anti-ZEBRA antibodies, which are consid-
ered the hallmark of EBV replication activation. As shown
in Figure 1B, we observed no association between EBV
load in blood and anti-ZEBRA titers. All the patients exhi-
biting anti-ZEBRA antibodies at high titers (≥5000) had
detectable anti-EA IgGs (data not shown).
Relationship between EBV status and clinical outcome by
univariate and multivariate analyses
In order to investigate the effect of EBV load (PBMCs
and tumor) on patient survival and its correlation with
clinicopathological factors, we conducted both univariate
and multivariate analyses in the following manner.
(i) For the univariate analysis of clinicopathological
factors, we first observed that some of the variables
demonstrated as having a significant effect (p <0.05) on
patient survival were, ranked in descending order of im-
portance: “relapse”, “lymph node invasion”, “anti-ZEBRA
titration”, and “tumor size” (Table 1 and see Additional
file 5: Figure S1). All these variables had a relative risk
(RR) >1, corresponding to a negative effect, i.e. a de-
crease in patient survival. Secondly, the Cox univariate
analysis revealed that the EBV variables (EBV-P and
EBV-T) produced no significant effect on patient sur-
vival, which correlated with the preliminary statistical
Mann–Whitney test (see above). Finally, the variables of
“tumor size” and “lymph node invasion” were found to
correlate (r = 0.43, p <0.05), and as a result, the “tumor
size” variable was no longer used in the following ana-
lyses. In order to determine if the replicating form of
EBV had any influence, we verified the impact of the
anti-ZEBRA antibody titers on patient survival. Interest-
ingly, patients with high titers of anti-ZEBRA antibodies
(≥5000) had a lower overall survival (p = 0.002).
(ii) To elucidate the possible relationship existing be-
tween various clinicopathological factors, we extended
our study with the Cox multivariate analysis. Given that
Figure 1 Quantification of EBV DNA in peripheral blood mononuclear cells (number of copies/μg) from the 85 BC patients. The
detection threshold was 5 and 10 copies EBV DNA/μg for PBMCs and tumor biopsies, respectively. Comparison with EBV load in tumors (number
of copies/μg) (A) and with anti-ZEBRA antibody titers (in absorbance of 450 nm) (B) (an optical density of 1 corresponds to a titer of 1000).
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it was applied to stratified data in the Cox analysis. In other
words, the baseline of hazard function in Cox models be-
came a function of relapse, as h0(t|Relapse). This has been
demonstrated in the Kaplan–Meier plot of survival func-
tions as S(t|Relapse = 0) > S(t|Relapse = 1). Eventually, we
found that the best Cox model for only the hazard function
excluding EBV variables involved the “lymph node inva-
sion” and “estrogen/progesterone receptor” variables, with
relative risks RR = 5.24 (95% CI = 1.61–17, p = 0.006) and
RR = 0.36 (95% CI = 0.13–1, p = 0.05), respectively. TheTable 1 Parameters of the univariate analysis of
clinicopathological factors
Explicative variables Relative risk (95% CI) p-value
Tumor size 2.04 (1.412–2.95) 0.00015
Grade 1 - -
Grade 2 1.38 (0.30–6.30) 0.679
Grade 3 2.92 (0.63–13.54) 0.171
Relapse 14.95 (5.67–39.44) <0.0001
EBV-T+ 0.795 (0.291–2.173) 0.65
EBV-P+ 1.05 (0.44–2.51) 0.91
ER/PR positive 0.48 (0.19–1.20) 0.116
HER-2 positive 2.71 (0.795–9.21) 0.111
Lymph node invasion 6.32 (2.31–17.3) 0.0003
Anti-ZEBRA antibody titration 4,63 (1.75–12.23) 0.002
EBV: Epstein-Barr virus; T+: detected in tumors; P+: detected in PBMCs; ER/PR:
estrogen/progesterone receptor; HER-2: human epidermal growth factor receptor
2; anti-ZEBRA: antibodies to BamH1 Z Epstein-Barr replication activator.Cox multivariate analysis demonstrated that five clini-
copathological variables had a significant effect on pa-
tient survival, either independently or in correlation
with each other. These consisted of the “lymph node in-
vasion”, “grade”, “HER-2”, and the two EBV variables
(EBV-P and EBV-T), of which “lymph node invasion”
also appeared significant in the univariate analysis. As
presented in Table 2, EBV-T and, to a lesser extent,
EBV-P were independent predictive factors for overall
survival. When we considered the relationship between
EBV status (EBV-T and EBV-P) and the grade, however,
we found that the higher the grade, the better the sur-
vival for EBV-T+ patients (RR = 0.0082), as well as for
EBV-P+ patients, yet to a lesser extent (RR = 0.16). A
comparison of the two models led to the conclusion that
patient survival, when analyzed without EBV variables
(h1(t) model) and with EBV variables (h2(t) model), differed
significantly (p = 0.0004). This led us to summarize the
multivariate analysis results as follows: (i) For patient sur-
vival vs. EBV status, EBV infection globally improved sur-
vival, as EBV-P+ and EBV-T+ patients appeared to exhibit
higher survival rates than EBV-P− and EBV-T− patients, re-
gardless of relapses (Figure 2). At 60 months following BC
diagnosis, the increase in survival for non-relapsing EBV-
positive patients, in comparison with those free of EBV,
was approximately 15%, whereas that achieved for relaps-
ing EBV-positive patients, in comparison with those free of
EBV, was only 6%; (ii) In terms of EBV-T vs. EBV-P effect
on patient survival, EBV-T+ patients exhibited better
survival than the EBV-P+ patients. Figure 3 displays the
Table 2 Parameters of the multivariate (Cox model) analysis of clinicopathological factors
Explicative variables Relative risk (95% CI) p-value
EBV-T+ 2.36.104 (152.9-3.7 106) <0.0001
Grade 11.52 (2.28-58.28) 0.003
EBV-P+ 122 (1.5-9.8 103) 0.03
Lymph node invasion 16.59 (2.5-110) 0.004
EBV-T+: grade 0.0082 (0.00071-0.0094) 0.0001
EBV-P+: HER-2 254 (7.88–8.19 103) 0.002
EBV-P+: grade 0.16 (0.03-0.96) 0.045
EBV: Epstein-Barr virus; T+: detected in tumors; P+: detected in PBMCs; HER-2: human epidermal growth factor receptor 2.
The hazard function for the model with EBV variables reads as: h2 tð Þ ¼ h0 tjRelapseð Þ  exp β21  Lympþ β22  EBV‐Pþ β23  EBV‐Tþ β24  Gradeþγ1  EBV‐P: Gradeþ γ2  EBV‐T: Gradeþ γ3  EBV‐P: HER2
 
.
The relative risk (RR) >1 corresponds to a negative effect, i.e. a decrease in patient survival, while an RR <1 corresponds to a positive effect, i.e. an increase in
patient survival. “95% CI” stands for the confidence interval at 95%. The variable “Grade” includes all grades.
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tients, in comparison with those free of EBV. The EBV-T+
patients presented a 32% and 8% increase in life expect-
ancy, without and with relapse, respectively, in comparison
with those free of EBV, while the increase achieved for
EBV-P+ patients was 12% and 6%, respectively.
Functional evaluation of T/NK cells and clinical outcome
We assessed the frequency of immunocompetent cells in
peripheral blood, as well as TNF-α and IFN-γ production,
in order to identify the mechanism by which EBV oper-
ates. For EBV status and cumulative survival, the 35 BC
patients investigated here were not found to differ from
the other 50 (see Additional file 6: Figure S4). Initially, we
stimulated the PBMCs with iono/PMA and determined
cytokine production as a read-out of cell activation. The
IFN-γ production of circulating PBMCs was much greater
in EBV-positive patients (EBV-P+ or EBV-T+) compared to
other groups and controls (p = 0.04 r = 0.36). In a second
step, we investigated both peripheral T-cell and NK-cell
response upon PMA/ionomycin activation in BC patientsFigure 2 Relative effect of EBV infection in PBMCs and tumor tissue v
relapses. Relapse 0 means “no relapse”; relapse 1 means “relapse diagnoseversus the control group. Our findings indicated that the
frequency of IFN-γ+/TNF-α+ producing NK cells exhibited
the same pattern, with similar mean values (16.2% ± 11) in
both relapsing and non-relapsing groups, and regardless
of EBV status, with no difference revealed in the control
group (15.8% ± 15). We assessed the amount of TNF-α in
an IFN-γ−/TNF-α+ NK cell subset and found it to be
higher in non-relapsing patients than in those who under-
went relapse. This increase of cytokine production corre-
lated with a higher survival rate (Figure 4A). Nevertheless,
we noticed that the non-relapsing patients exhibited an in-
creasing frequency of IFN-γ+/TNF-α+ NK cells, though a
non-significant trend in patient survival (p >0.05) was ob-
served. Following this, we examined the distribution of T
lymphocytes along with their capacity to produce TNF-α
upon stimulation with PMA/ionomycin. Our findings in-
dicated that TNF-α production was significantly higher in
the non-relapsing group than in the relapsing, suggesting
a significant correlation between the amount of TNF-α in
IFN-γ−/TNF-α+producing T cells and increased survival
(p = 0.02) (Figure 4B). To investigate further, we divided theersus no EBV on survival as a function of time for different
d”.
Figure 3 Effect of EBV-T and EBV-P on the increase in patient survival as a function of time for different relapses. At 60 months
post-diagnosis, the increase in survival is 32% and 8%, respectively, without and with relapse for “EBV-T” patients, versus 12% and 6%, respectively
without and with relapse for “EBV-P” patients. Relapse 0 means “no relapse”; relapse 1 means “relapse diagnosed”. EBV-T + and EBV-P + represent
patients with detectable EBV DNA in tumor tissue and PBMCs, respectively.
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with each group then further divided according to EBV sta-
tus (EBV-P+/EBV-T+, EBV-P+/EBV-T−, EBV-P−/EBV-T+,
and EBV-P−/EBV-T−). We observed that the frequency (%)
of PBMCs producing IFN-γ was similar across all groups,
with a mean value of 9.1% ± 6.2. The primary difference,
however, was focused in the intensity of IFN-γ expression
(MIF) (Figure 5). The results indicated that a significant
amount of IFN-γ was produced by the peripheral blood
mononuclear cells in EBV-P+/EBV-T+ patients, with a
mean value of IFN-γ expression from T cells calculated as
555 ± 226 versus 82 ± 10 in EBV-P+/ EBV-T− patients, and
164 in the single EBV-P−/ EBV-T+ patient. As displayed in
Figure 5, non-relapsing BC patients with EBV detected inA
Figure 4 Clinical outcome of 35 patients with BC (out of all 85 patien
cytokine production (16 healthy individuals enrolled as negative cont
NK cells > the control group (solid green line) and < the control group (red
detected in PBMCs in 66%, and in tumor tissues in 17%. The clinical outcom
by peripheral T cells. Overall survival (B) in patients with TNF-α expression
group (red dashed).both tumor tissue and PBMCs strongly correlated with a
high production of IFN-γ.
Discussion
A recent literature review evaluated the methodology of
all studies published to date, remarking that only four of
the 30 studies convincingly demonstrated the presence
of EBV in breast tumor tissue [32]. While several re-
search investigations have explored EBV DNA presence
in tumor tissue by using Q-PCR [4,6,13,14,18,20], their
findings have been extremely divergent, with no consen-
sus reached. Nevertheless, it is worth mentioning that
the most recent report, published in 2011, found that
EBV DNA was present in 33.2% of cases [6]. AnotherB
ts) and correlation with frequency of peripheral NK cells and
rols). Overall survival (A) in patients with TNF-α expression (MIF) by
dashed line). In this group of 35 patients, copies of EBV genomes were
e of the 35 patients with BC and correlation with TNF- α expression
(MIF) by T cells > the control group (solid green line) and < the control
Figure 5 Synthetic diagram analyzing the impact of the IFN-γ production by peripheral blood mononuclear cells on the clinical
outcome according to EBV status in blood and tumor tissue. PBMC EBV− means <5 EBV DNA copies/μg, PBMC EBV+ means >5 EBV DNA
copies/μg. Tumor EBV− means <10 EBV DNA copies/μg and tumor EBV+ means >10 EBV DNA copies/μg. The intensity of the color is proportional
to the amount of cytokine (IFN- γ or TNF-α) production (the black color indicates negative or control basal level, the red color indicates positive
or high level).
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was detectable when using qPCR in 46% of cases, usually
in low copy numbers and heterogeneously distributed.
Their results also revealed that the viral load highly var-
ied from tumor to tumor and suggested that EBV infec-
tion, at a late stage of tumor development, may enhance
its oncogenic properties, such as invasion, angiogenesis,
and metastasis. For these reasons, we opted for the
qPCR method to investigate the EBV DNA extracted
from the whole tumor specimen. With this technique,
we uncovered a positive ratio of 25.8% for EBV in tumor
tissue (EBV-T+ patients) and 47% in peripheral blood
(EBV-P+). As has been demonstrated by other publica-
tions before us [14], the presence of EBV in the tumor
specimens coupled with no detection of EBV genomic
DNA in the peripheral blood, and vice-versa, that we ob-
served are consistent with the epithelial nature of the
virus. In this study, we examined both neoplastic breast
tissue and matched peripheral blood samples for EBV
DNA, in the aims of reporting the impact of EBV on the
clinical outcome of BC patients, regardless of tumor
histology or treatment regimen. The most prominent re-
sults were our ability to demonstrate, through multivari-
ate statistical analysis, that the presence of EBV DNA atany level in both circulating PBMC and tumors was as-
sociated with increased lifetime for BC patients. When
interpreting the multivariate analysis results, the benefi-
cial role of EBV in the context of BC outcome is particu-
larly striking for patients with high grade tumors, and
this effect is all the more impressive for EBV-T+ patients,
compared to EBV-P+ patients. Given that both periph-
eral and tumor EBV DNA loads were demonstrated to
correspond primarily to a latent form of the virus
[11,33-36], we could posit that this latent form, whether
tumoral or circulatory, could be beneficial for the pa-
tient. In contrast, when verifying the impact of the anti-
ZEBRA antibody titers on patient survival, we demon-
strated that patients with anti-ZEBRA antibodies at high
titers (≥5000) exhibited poorer overall survival (p =
0.002). This observation was in line with other studies
investigating other EBV-associated tumors, such as
Hodgkin’s Lymphoma (HL) or non-Hodgkin lymphomas
[30,37]. Interestingly, Arbach et al. [4] succeeded in de-
tecting ZEBRA transcripts in two of the eight BC biopsy
specimens. In BC cases, the expression of ZEBRA could
be deleterious, namely because ZEBRA is able to induce
metalloproteinase expression that may contribute to in-
vasion and metastasis [38]. Two other interesting
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http://www.biomedcentral.com/1471-2407/14/665features were: (i) the absence of correlation between
EBV peripheral load and anti-ZEBRA antibodies; (ii) the
absence of correlation between EBV load in peripheral
blood and tumor biopsies. These figures could therefore
demonstrate a different pattern of EBV, in the context of
BC, compared to other EBV-positive cancers originating
in the epithelial cells [30,39-41]. All in all, these findings
suggest a compartmentation between the breast tumor
area and periphery. In this study, we uncovered a new
significance of the peripheral and tumoral global EBV
load, which appeared to represent not only a harmless
passenger, as suggested by others [12], but also a con-
tributory function to the body’s immune reaction against
the tumor. Interestingly, a recent report noted that the
EBV may contribute to the risk of BC, and that this con-
tribution may be modified by genetic variations in IFN-γ
[42]. In our study, the most critical results were the fre-
quency of interferon-γ producing PBMCs in non-
relapsing patients with detectable EBV in blood and
tumor tissue. Another critical finding was the greater
quantities of TNF-α in the NK cells and T lymphocytes
of patients with favorable outcome, as demonstrated by
the survival curves. This suggests that these cells are en-
gaged in a Th1-oriented immune activation process, cre-
ating an anti-tumoral response in a non-specific manner,
with the EBV possibly playing a facilitating role in this
response. It appeared possible that the presence of EBV,
in tissue and the periphery, stimulated the host immune
response, boosting both IFN-γ and TNF-α levels, leading
to a favorable outcome in these patients. Nevertheless,
the role of the EBV in both blood and tumors in this im-
mune stimulation remained unclear. Taking into account
the multivariate analysis and model comparison ap-
proach, therefore, and considering the clinical outcome,
we could speculate that the role of the EBV is more pro-
nounced in tumor tissue than in peripheral blood. In
contrast to what has previously been described, this
study may postulate that the EBV, in its latent form, can
act as a co-factor for the anti-tumoral immune response.
It is worth mentioning similar results obtained recently
in Hodgkin’s disease (HD) cases, concerning another
EBV-related tumor [43]. In this context, other authors
analyzing classical Hodgkin’s lymphoma tissue found
that the outcome of the patients may be related to the
tumor microenvironment, which in turn may be influ-
enced by EBV infection, suggesting that the EBV could
favor a Th1-type immune response in a non-specific way,
demonstrating improved outcomes for EBV-positive pa-
tients compared to their EBV-negative counterparts
[44,45]. It is interesting to note that this effect has been re-
ported as being age-dependent in the case of EBV-positive
Hodgkin’s lymphoma [46]. Nevertheless, our population-
based study has led us to conclude that this effect exists
regardless of age stratification.The increased immune response exhibited by EBV-
T+/EBV-P+ patients could result from a cooperation be-
tween epithelial cells, dendritic cells, NK cells, and B or T
lymphocytes [47]. The frequency of T and NK cells produ-
cing IFN-γ, as well as the cytokine quantity at a single cell
level observed in EBV-T+/EBV-P+ patients, indicates that
the EBV, in its latent form, induces a prolonged state of
anti-tumor immune reaction. The durability of this reaction
led us to hypothesize that EBV infection represents a truly
symbiotic relationship, by means of heightened innate im-
mune activation, as was recently demonstrated with other
herpes viruses [48]. Accumulating evidence has indicated
that all three herpes virus subfamilies in latent forms in
humans involved chronic, low-level immune activation
accompanied by IFN-γ and TNF-α secretion in response
to frequent yet subclinical viral reactivation [49-51]. The
plausible hypothesis to explain this immune activation
could also involve either the chronic presentation of viral
antigens or trans-activation of HERV-K [52,53], or both,
resulting in prolonged T–cell activation and IFN-γ secre-
tion. This is likely given that HERV surface envelope pro-
teins have been demonstrated to provide target antigens
recognizable by cytotoxic T-cells, antibodies [53], or den-
dritic cells, with the capacity to support a Th1-like process
of Th cell differentiation [54]. The negative confounding
and apparent link between tumor grade and favorable out-
come for EBV-T+ patients could be accounted for by this
putative viral cross-talk, as previous studies have demon-
strated that the higher the tumor grade, the greater the ex-
pression of tumor HERV [55].
Conclusion
Our findings have revealed the following unexpected
properties of this so-called “double faceted” EBV: (i) the
latent form of this virus, measured and quantified by the
tumor viral EBV DNA, confers a survival advantage to
BC patients; (ii) there is an association between high
anti-ZEBRA titers and poor outcome, though the high
anti-ZEBRA response could be the result of late stage
cancer and not the cause of poor outcome. Given that
this study assessing the beneficial effects of the EBV was
conducted over a long time period, these results are a
relevant basis for future studies involving a larger patient
population.
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